EE200100123A - CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon - Google Patents

CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon

Info

Publication number
EE200100123A
EE200100123A EEP200100123A EEP200100123A EE200100123A EE 200100123 A EE200100123 A EE 200100123A EE P200100123 A EEP200100123 A EE P200100123A EE P200100123 A EEP200100123 A EE P200100123A EE 200100123 A EE200100123 A EE 200100123A
Authority
EE
Estonia
Prior art keywords
lymphocytes
population
binding agent
memory effector
effector
Prior art date
Application number
EEP200100123A
Other languages
English (en)
Estonian (et)
Inventor
Magilavy Daniel
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200100123A publication Critical patent/EE200100123A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200100123A 1998-08-31 1999-08-31 CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon EE200100123A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9845698P 1998-08-31 1998-08-31
PCT/US1999/020026 WO2000012113A2 (en) 1998-08-31 1999-08-31 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions

Publications (1)

Publication Number Publication Date
EE200100123A true EE200100123A (et) 2002-06-17

Family

ID=22269362

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100123A EE200100123A (et) 1998-08-31 1999-08-31 CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon

Country Status (26)

Country Link
US (2) US20020009446A1 (cs)
EP (1) EP1109570B1 (cs)
JP (1) JP2002523071A (cs)
KR (1) KR20010085687A (cs)
CN (1) CN100473417C (cs)
AT (1) ATE306932T1 (cs)
AU (1) AU764020B2 (cs)
BR (1) BR9913285A (cs)
CA (1) CA2339299C (cs)
CZ (1) CZ298238B6 (cs)
DE (1) DE69927831T2 (cs)
DK (1) DK1109570T3 (cs)
EA (1) EA005948B1 (cs)
EE (1) EE200100123A (cs)
ES (1) ES2252999T3 (cs)
HK (2) HK1038186A1 (cs)
HU (1) HUP0103563A3 (cs)
IL (2) IL141486A0 (cs)
IS (1) IS5848A (cs)
MX (1) MXPA01002111A (cs)
NO (1) NO20010956L (cs)
NZ (1) NZ510831A (cs)
PL (1) PL346339A1 (cs)
TR (1) TR200100607T2 (cs)
WO (1) WO2000012113A2 (cs)
ZA (1) ZA200101213B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
IL141486A0 (en) * 1998-08-31 2002-03-10 Biogen Inc Pharmaceutical compositions containing a cd2 binding agent
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2436411A1 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Methods for treating or preventing skin disorders using cd2-binding agents
EP1419236A4 (en) * 2001-07-24 2005-08-03 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US20080241884A1 (en) * 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070172478A1 (en) * 2004-02-06 2007-07-26 Astellas Us Llc Methods of treating skin disorders
MXPA06012744A (es) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento.
US7662921B2 (en) * 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2603203T3 (es) 2006-05-12 2017-02-24 Ith Immune Therapy Holdings Ab Método y medio para tratar la enfermedad inflamatoria intestinal
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
EA023912B1 (ru) 2008-09-10 2016-07-29 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительных состояний
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
CA3094756A1 (en) * 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
DE3377363D1 (en) * 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (ja) * 1985-11-26 1995-07-12 アスモ株式会社 ダイカスト鋳造金型への離型剤塗布方法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
US5547853A (en) * 1991-03-12 1996-08-20 Biogen, Inc. CD2-binding domain of lymphocyte function associated antigen 3
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
US5511563A (en) * 1991-06-21 1996-04-30 Diamond; Donald A. Apparatus and method for treating rheumatoid and psoriatic arthritis
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0786255B1 (en) * 1991-10-07 2001-12-12 Biogen, Inc. Methods of improving allograft or xenograft tolerance by administration of an LFA-3 or CD2 binding protein
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
EP0804459A4 (en) * 1995-01-16 1999-05-26 Commw Scient Ind Res Org CONJUGATES THERAPEUTIC COMPOUND - FATTY ACID
IL141486A0 (en) * 1998-08-31 2002-03-10 Biogen Inc Pharmaceutical compositions containing a cd2 binding agent
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
CA2436411A1 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Methods for treating or preventing skin disorders using cd2-binding agents
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease

Also Published As

Publication number Publication date
EA005948B1 (ru) 2005-08-25
EA200100304A1 (ru) 2001-10-22
DK1109570T3 (da) 2006-03-06
ATE306932T1 (de) 2005-11-15
AU6024499A (en) 2000-03-21
HUP0103563A2 (hu) 2002-01-28
US20020009446A1 (en) 2002-01-24
DE69927831T2 (de) 2006-07-20
AU764020B2 (en) 2003-08-07
IL141486A (en) 2007-12-03
WO2000012113A2 (en) 2000-03-09
KR20010085687A (ko) 2001-09-07
CA2339299A1 (en) 2000-03-09
CA2339299C (en) 2009-02-10
EP1109570B1 (en) 2005-10-19
IL141486A0 (en) 2002-03-10
ES2252999T3 (es) 2006-05-16
HUP0103563A3 (en) 2004-04-28
CN100473417C (zh) 2009-04-01
BR9913285A (pt) 2001-05-15
JP2002523071A (ja) 2002-07-30
DE69927831D1 (de) 2006-03-02
IS5848A (is) 2001-02-16
US20060233796A1 (en) 2006-10-19
EP1109570A2 (en) 2001-06-27
ZA200101213B (en) 2002-02-13
PL346339A1 (en) 2002-02-11
MXPA01002111A (es) 2003-03-27
NZ510831A (en) 2002-12-20
CZ2001725A3 (cs) 2001-08-15
NO20010956L (no) 2001-04-30
CN1315866A (zh) 2001-10-03
TR200100607T2 (tr) 2001-06-21
HK1038186A1 (en) 2002-03-08
CZ298238B6 (cs) 2007-08-01
HK1040186A1 (zh) 2002-05-31
WO2000012113A3 (en) 2000-06-29
NO20010956D0 (no) 2001-02-26

Similar Documents

Publication Publication Date Title
EE200100123A (et) CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
EA200100103A1 (ru) Ингибиторы адгезии клеток
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
BG101717A (en) Inhibitors of microsomal triglyceride transfer protein and method
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
NO982126D0 (no) Polymere br÷nnkomplotteringssammensetninger og hjelpesammensetninger og fremgangsmÕter for anvendelse av disse
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
MX9603845A (es) Profarmacos de antagonistas del receptor de morfolino-taquiquinina.
ZA93811B (en) Methods of treating inflammatory dermatoses.
ZA983451B (en) Substituted imidazoles useful in the treatment of inflammatory diseases.
ATE267168T1 (de) Beta-alanin-derivate als zell-adhäsions- inhibitoren
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
EE04111B1 (et) Raku adhesiooni inhibiitorid, nende kasutamine janeid sisaldavad farmatseutilised kompositsioonid
BR9907788A (pt) Agentes antiinflamatórios seletivos paraglicocorticóides
NO20006600D0 (no) Ikke-peptidylinhibitorer av VLA-4-avhengig cellebinding nyttig for behandling av inflammatoriske, autoimmune og respiratoriske sykdommer
EP0702566A4 (en) INHIBITION OF THE MIGRATION INHIBITION FACTOR IN THE TREATMENT OF DISEASES IN WHICH A CYTOKIN-MEDIATED TOXICITY PLAYS A ROLE
FI971756A (fi) CD23:een sitoutuvia aineita
NO20004052L (no) Glukokortikoidselektive antiinflammatoriske midler
DE69628302D1 (de) Milchige reinigungs- und/oder desinfektionsmittelzusammensetzungenfür harte oberflächen.
ES2172536T3 (es) Liberacion y movilizacion de celulas hematopoyeticas.
ATE186121T1 (de) Verfahren zur bestimmung des präthrombotischen status
DE69632580D1 (de) Ausgabestufe für Speicheranlage und für Niederspannungsanwendungen
ZA973571B (en) Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2,6-di-alkyl-4-silyl-phenols.
GB9312315D0 (en) Leukocyte adhesion assay
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria

Legal Events

Date Code Title Description
HC1A Change of owner name